Clinical Pharmacy Specialist Implementation of Lisinopril Therapy in Patients with Coronary Artery Disease and Diabetes Mellitus

Pharmacotherapy

Volumn 23, Issue 12 I, 2003, Pages 1564-1572

  McConnell, Karen J ^a,b,e   Humphries, Tammy L ^a,b   Raebel, Marsha A ^a,c   Merenich, John A ^a,b,d  

^a UNIVERSITY OF COLORADO   (United States)

^b Kaiser Found Hlth Plan of Colorado   (United States)

^c CLINICAL RESEARCH UNIT   (United States)

^d University of Colorado Health Sciences Center   (United States)

^e KAISER PERMANENTE   (United States)

Author keywords

Coronary artery disease; Diabetes mellitus; Lisinopril; Pharmacist

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; POTASSIUM;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL PHARMACY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PHARMACY; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PHARMACIST; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; TITRIMETRY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; FEMALE; HUMANS; LISINOPRIL; MALE; PHARMACY SERVICE, HOSPITAL; PROSPECTIVE STUDIES;

EID: 0344011145     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.15.1564.31963     Document Type: Article

References (17)

1. American Heart Association. 2000 heart and stroke statistical update. Dallas TX: American Heart Association, 1999.
2. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355(9200):253-9.
3. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;318:1429-35.
4. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
5. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
6. ISIS-4 Collaborative Group. ISIS-4: a randomized factorial trial assessing early captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
7. Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997;96(12):4239-45.
8. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial (SAVE). N Engl J Med 1992;327:669-77.
9. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
10. Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
11. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression. Ann Intern Med 1993;118(2):129-38.
12. EUCLID Study Group. Randomized placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;346:1787-92.
13. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
14. Merenich JA, Lousberg TR, Brennan SH, Calonge NG. Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience). Am J Cardiol 2000;85:36A-42.
15. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP). Am J Cardiol 2001;87(7):819-22.
16. Johnson JA, Parker RB, Patterson JH. Heart failure. In: DiPiro JI, ed. Pharmacotherapy: a pathophysiologic approach, 5th ed. New York: McGraw-Hill, 2002:185-218.
17. Koenig W. Ramipril vs lisinopril in the treatment of mild to moderate primary hypertension: a randomised double-blind multicenter trial. Drug Invest 1992;4:450-7.